Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C.

Expert opinion on drug metabolism & toxicology - 1 Jul 2015

Rivero-Juarez Antonio, Camacho Angela, Rivero Antonio

Abstract excerpt

INTRODUCTION: Telaprevir is one of the first direct-acting antiviral drugs approved for the treatment of the hepatitis C virus (HCV) genotype 1. Following its approval in 2011, new data regarding the pharmacokinetics and pharmacodynamics were reported, leading to important clinical applications. AREAS COVERED: This article reviews the pharmacokinetic and pharmacodynamic properties of telaprevir for the treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Interactions
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C

Share to Oligopeptides

Source

Identifiers

PMID: 26004270
DOI: 10.1517/17425255.2015.1049532

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C.PMID 26004270Read ↗

Telaprevir for the treatment of chronic hepatitis C infection.Semantic proximity Read ↗

[Biochemical and pharmacological features of telaprevir].Semantic proximity Read ↗

Telaprevir: a new hope in the treatment of chronic hepatitis C?Semantic proximity Read ↗

Telaprevir: a hepatitis C NS3/4A protease inhibitor.Semantic proximity Read ↗

Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.Semantic proximity Read ↗

[Telaprevir: new possibilities for antiviral treatment in patients with chronic hepatitis C].Semantic proximity Read ↗

Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.Semantic proximity Read ↗

[Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects].Semantic proximity Read ↗

Optimal treatment with telaprevir for chronic HCV infection.Semantic proximity Read ↗

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.Semantic proximity Read ↗

Telaprevir.Semantic proximity Read ↗

Drugs in development for chronic hepatitis C: a promising future.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.